QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 singular-genomics-enters-into-agreement-to-be-acquired-by-deerfield-for-20-in-cash-per-share

Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging nove...

 singular-genomics-sys-q3-eps-672-beats-786-estimate-sales-40600k-miss-82500k-estimate

Singular Genomics Sys (NASDAQ:OMIC) reported quarterly losses of $(6.72) per share which beat the analyst consensus estimate of...

 singular-genomics-receives-non-binding-acquisition-proposal-from-concentra-biosciences-and-tang-capital-to-acquire-all-of-the-companys-outstanding-shares-of-common-stock-for-1200-per-share-in-cash

Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomi...

 whats-going-on-with-singular-genomics-stock-friday

Singular Genomics shares are trading higher Friday after the company announced it received a non-binding acquisition proposal f...

 singular-genomics-sys-q2-2024-gaap-eps-857-beats-895-estimate-sales-73700k-beat-40000k-estimate

Singular Genomics Sys (NASDAQ:OMIC) reported quarterly losses of $(8.57) per share which beat the analyst consensus estimate of...

 goldman-sachs-maintains-neutral-on-singular-genomics-sys-lowers-price-target-to-65

Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target...

 goldman-sachs-maintains-neutral-on-singular-genomics-sys-lowers-price-target-to-075

Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION